Xalkori (crizotinib) coverage policy
Defines prior authorization criteria, covered indications, documentation requirements, and authorization durations for Xalkori (crizotinib) across FDA-approved and compendial uses for commercial members.
No material clinical or coverage changes.
Coverage Summary
Coverage stance: covered_with_criteria. Defines prior authorization criteria, covered indications, documentation requirements, and authorization durations for Xalkori (crizotinib) across FDA-approved and compendial uses for commercial members. General coverage statement: Drugs indicated below are covered when all applicable approval criteria are met and the member has no exclusions to the prescribed therapy. Requested drug must be Xalkori (crizotinib) (brand or generic, any dosage form or strength) and the member must have no exclusions to the prescribed therapy.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.